Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04988243
Other study ID # DB001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2021
Est. completion date August 2028

Study information

Verified date August 2021
Source CCRF Inc., Beijing, China
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to observe the safety and effectiveness of transcatheter aortic valve replacement in patients with aortic valve stenosis in a real-world clinical practice environment.


Description:

This study is a prospective / retrospective, multicenterstudy after listing. The researchers preliminarily confirmed that they could be enrolled in this study according to the diagnosis of the subjects' medical history. After fully informed, they signed the informed consent, and met the TAVR inclusion requirements (see the inclusion criteria for details). At the same time, they registered the subjects in multiple centers. After the start of the trial, the participants were enrolled in the study, All the subjects who met the inclusion criteria but did not meet the discharge criteria were registered in the central registration system. The patients were followed up for 30 days, 6 months and 12 months, and followed up by telephone for 2, 3, 4 and 5 years.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 320
Est. completion date August 2028
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Severe aortic valve stenosis, defined as follows: 1. Symptomatic patients: - The mean differential pressure measured by echocardiography = 40mm Hg - Or peak aortic ejection = 4.0 m / S - Or aortic valve area = 1.0cm ²( Or AVA index = 0.6 cm2 / m2) 2. Asymptomatic patients: - Severe aortic stenosis and aortic valve area = 1.0cm ²( 6 cm2 / m2) with aortic ejection peak value = 5.0 M / s or mean pressure difference measured by --echocardiography = 60 mm Hg; - Or aortic valve area = 1.0cm ²( Or AVA index = 0.6 cm2 / m2), combined with aortic ejection peak = 4.0 m / s or average differential pressure measured by echocardiography = 40 mm Hg, combined with limited exercise tolerance test, abnormal blood pressure response or arrhythmia; - Or aortic valve area = 1.0cm ²( Or AVA index = 0.6 cm2 / m2), combined with aortic ejection peak = 4.0 m / s or average differential pressure measured by echocardiography = 40 mm Hg, combined with LVEF < 50% 2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement 3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up; 4. Be able to contact the subjects or their legal guardians / relatives; 5. The medical record records the subjects who have died and can't get any contact information of the subjects( (for dead cases only) Note: for dead subjects, they must meet 1, 2 and 5 at the same time before they can be included in the group. Exclusion Criteria: 1. Contraindications to any artificial biological valve implantation; 2. Any known allergies or contraindications; - Aspirin or heparin and bivalirudin; - Tigrelol and clopidogrel; - Nickel titanium alloy; - Contrast medium; 3. The patient is currently participating in drug or device research; 4. The patient is pregnant or lactating; 5. Aortic annulus diameter < 17 mm or > 32 mm; 6. The diameter of approach vessel was less than 5.0mm; 7. The investigator believes that the patient is not suitable to participate in this study or complete the follow-up specified in the protocol;

Study Design


Related Conditions & MeSH terms


Intervention

Other:
All aortic valve products on the market
Subjects with severe aortic valve stenosis Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up; Be able to contact the subjects or their legal guardians / relatives; The medical record records the subjects who have died and can't get any contact information of the subjects( (for dead cases only) Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
CCRF Inc., Beijing, China Hangzhou Qiming Medical Instrument Co., Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Primary end point: the incidence of all-cause death 12 months after operation After subjects completed aortic valve replacement surgery, whether prospectively or retrospectively, all-cause mortality at 12 months after operation was collected according to the time node of subjects' enrollment 12 months after aortic valve replacement
Secondary The compound incidence of death, surgery, severe stroke, life-threatening bleeding, serious vascular complications and acute renal failure (within 30 days after operation); The compound incidence of death, surgery, severe stroke, life-threatening bleeding, serious vascular complications and acute renal failure (within 30 days after operation); Within 30 days after aortic valve replacement
Secondary The implantation rate of permanent pacemaker within 30 days; The implantation rate of permanent pacemaker within 30 days; Within 30 days after aortic valve replacement
Secondary All stroke (disabled or not disabled) within 12 months and 2, 3, 4 and 5 years All stroke (disabled or not disabled) within 12 months and 2, 3, 4 and 5 years; 12 months and within 2, 3, 4 and 5 years
Secondary the incidence of life-threatening bleeding within 12 months and 2, 3, 4 and 5 years; the incidence of life-threatening bleeding within 12 months and 2, 3, 4 and 5 years; 12 months and within 2, 3, 4 and 5 years
Secondary The incidence of reoperation due to dysfunction of prosthetic valve within 12 months and 2,3,4,5 years; The incidence of reoperation due to dysfunction of prosthetic valve within 12 months and 2,3,4,5 years; 12 months and within 2, 3, 4 and 5 years
Secondary The incidence of readmission due to symptoms and signs of aortic valve disease within 12 months and 2,3,4,5 years; The incidence of readmission due to symptoms and signs of aortic valve disease within 12 months and 2,3,4,5 years; 12 months and within 2, 3, 4 and 5 years
Secondary The incidence of prosthetic valve dysfunction at 12 months (moderate or severe stenosis or reflux by ultrasonography); The incidence of prosthetic valve dysfunction at 12 months (moderate or severe stenosis or reflux by ultrasonography); 12 months and within 2, 3, 4 and 5 years
Secondary The incidence of thrombus in clinical and subclinical prosthetic heart valves at 12 months; The incidence of thrombus in clinical and subclinical prosthetic heart valves at 12 months; 12 months after aortic valve replacement
See also
  Status Clinical Trial Phase
Recruiting NCT05552352 - VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease N/A
Recruiting NCT06168123 - Future Optimal Research and Care Evaluation - Aortic Stenosis
Active, not recruiting NCT05182307 - DurAVR™ THV System: First-In-Human Study N/A
Recruiting NCT06156592 - Post Spinal Hemodynamic Changes in Aortic Stenosis and Mitral Regurgitation by VIS Index and Echocardiography
Completed NCT04259723 - Virtual Reality Assisted Conscious Sedation During TAVI N/A
Recruiting NCT05873816 - The PROTEMBO Trial N/A
Recruiting NCT04128384 - Infranodal Conduction Time During TAVR as Predictor of HAVB N/A
Recruiting NCT05024942 - LUS in Aortic Stenosis Patients Undergoing TAVR
Recruiting NCT05283356 - Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation Phase 4
Not yet recruiting NCT05847751 - The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis
Completed NCT02224066 - Platelet Reactivity After TAVI: A Multicenter Pilot Study Phase 4
Recruiting NCT06168370 - Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation N/A
Recruiting NCT05097183 - Validation of Accurate Commissural Alignment During Transcatheter Aortic Valve Implantation
Active, not recruiting NCT05712161 - Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study N/A